Phase I Study of SF1126 for Patients With Relapsed or Refractory Neuroblastoma
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2017
At a glance
- Drugs SF 1126 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 14 Aug 2017 Status changed from active, no longer recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 21 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.